Neurocrine Biosciences Inc (NASDAQ:NBIX) — Market Cap & Net Worth

$13.03 Billion USD · Rank #1808

Market Cap & Net Worth: Neurocrine Biosciences Inc (NBIX)

Neurocrine Biosciences Inc (NASDAQ:NBIX) has a market capitalization of $13.03 Billion ($13.03 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1808 globally and #666 in its home market, demonstrating a 1.22% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurocrine Biosciences Inc's stock price $131.78 by its total outstanding shares 100363463 (100.36 Million). Analyse NBIX cash flow metrics to see how efficiently the company converts income to cash.

Neurocrine Biosciences Inc Market Cap History: 2015 to 2026

Neurocrine Biosciences Inc's market capitalization history from 2015 to 2026. Data shows growth from $5.68 Billion to $13.23 Billion (9.85% CAGR).

Index Memberships

Neurocrine Biosciences Inc is a constituent of 6 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
ARCA Biotechnology BTK	$910.33 Billion	1.43%	#17 of 30
Dow Jones Biotechnology DJUSBT	$1.09 Trillion	1.20%	#11 of 39
NASDAQ Health Care IXHC	$2.41 Trillion	0.54%	#30 of 976
NASDAQ Composite IXIC	$38.77 Trillion	0.03%	#207 of 3165
S&P Midcap 400 MID	$3.36 Trillion	0.36%	#57 of 401
NASDAQ Biotechnology NBI	$1.67 Trillion	0.78%	#21 of 263

Weight: Neurocrine Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Neurocrine Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Neurocrine Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

4.98x

Neurocrine Biosciences Inc's market cap is 4.98 times its annual revenue

Industry average: 1.04x Higher than industry average

Latest Price to Earnings (P/E) Ratio

29.74x

Neurocrine Biosciences Inc's market cap is 29.74 times its annual earnings

Industry average: 8.30x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$3.88 Billion	$15.00 Million	-$141.09 Million	258.94x	N/A
2017	$7.79 Billion	$161.63 Million	-$142.54 Million	48.18x	N/A
2018	$7.17 Billion	$451.24 Million	$21.11 Million	15.88x	339.49x
2019	$10.79 Billion	$788.10 Million	$37.00 Million	13.69x	291.57x
2020	$9.62 Billion	$1.05 Billion	$407.30 Million	9.20x	23.62x
2021	$8.55 Billion	$1.13 Billion	$89.60 Million	7.54x	95.40x
2022	$11.99 Billion	$1.49 Billion	$154.50 Million	8.05x	77.59x
2023	$13.22 Billion	$1.89 Billion	$249.70 Million	7.01x	52.96x
2024	$13.70 Billion	$2.36 Billion	$341.30 Million	5.82x	40.14x
2025	$14.23 Billion	$2.86 Billion	$478.60 Million	4.98x	29.74x

Competitor Companies of NBIX by Market Capitalization

Companies near Neurocrine Biosciences Inc in the global market cap rankings as of May 2, 2026.

Key companies related to Neurocrine Biosciences Inc by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#499	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#525	Zoetis Inc	NYSE:ZTS	$50.31 Billion	$114.16
#526	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$50.29 Billion	CN¥53.88
#572	GALDERMA GROUP AG	NYSE:GALDY	$45.88 Billion	$42.09

Neurocrine Biosciences Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Neurocrine Biosciences Inc's market cap moved from $5.68 Billion to $ 13.23 Billion, with a yearly change of 9.85%.

Year	Market Cap	Change (%)
2026	$13.23 Billion	-7.09%
2025	$14.23 Billion	+3.90%
2024	$13.70 Billion	+3.60%
2023	$13.22 Billion	+10.31%
2022	$11.99 Billion	+40.24%
2021	$8.55 Billion	-11.14%
2020	$9.62 Billion	-10.83%
2019	$10.79 Billion	+50.53%
2018	$7.17 Billion	-7.96%
2017	$7.79 Billion	+100.49%
2016	$3.88 Billion	-31.59%
2015	$5.68 Billion	--

End of Day Market Cap According to Different Sources

On May 2nd, 2026 the market cap of Neurocrine Biosciences Inc was reported to be:

Source	Market Cap
Yahoo Finance	$13.03 Billion USD
MoneyControl	$13.03 Billion USD
MarketWatch	$13.03 Billion USD
marketcap.company	$13.03 Billion USD
Reuters	$13.03 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Neurocrine Biosciences Inc

NASDAQ:NBIX USA Drug Manufacturers - Specialty & Generic

Market Cap

$13.23 Billion

Market Cap Rank

#1808 Global

#666 in USA

Share Price

$131.78

Change (1 day)

+0.08%

52-Week Range

$109.75 - $155.63

All Time High

$155.63